Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)

In current clinical guidelines, such as those provided by the National Comprehensive Cancer Network (NCCN), evidence for treatment is based on a small clinical trial that included patients with HLRCC. They support the use of the combination of erlotinib and bevacizumab as the first therapeutic optio...

Full description

Bibliographic Details
Main Authors: Ibon Gurruchaga Sotés, Ana Nuño Alves, Sandra Vicente Arregui, Carmen Santander Lobera
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Current Oncology
Subjects:
hereditary leyomiomatosis
renal cell cancer
pembrolizumab
axitinib
Online Access:https://www.mdpi.com/1718-7729/28/4/216

Similar Items

Similar Items